SAB Biotherapeutics Highlights Diabetes Trial Progress, Human Antibody PlatformMarketBeat · 1 day ago
SAB BIO to Participate in Chardan 10th Annual Healthcare ConferenceGlobeNewsWire · Oct 14, 2026
SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 DiabetesGlobeNewsWire · Oct 13, 2026
SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research CongressGlobeNewsWire · Oct 1, 2026
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock Rated “Moderate Buy” by Sell-Side AnalystsDefense World · Sep 30, 2026
SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of DiabetesGlobeNewsWire · Sep 22, 2026SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.28 | -$0.28 | Beat |
| May 12, 2026 | -$0.20 | -$0.35 | Miss |
| Mar 9, 2026 | -$0.16 | -$0.46 | Miss |
| Nov 14, 2025 | -$0.59 | -$0.21 | Beat |
| Aug 7, 2025 | -$0.82 | -$1.09 | Miss |
| May 9, 2025 | -$1.00 | -$0.56 | Beat |